Selective glycopolymer inhibitors of galectin-3: supportive anti-cancer agents protecting monocytes and preserving interferon-gamma function
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F25%3A00635780" target="_blank" >RIV/61388971:_____/25:00635780 - isvavai.cz</a>
Alternative codes found
RIV/61389013:_____/25:00635780 RIV/68407700:21460/25:00390009 RIV/00216208:11310/25:10498624
Result on the web
<a href="https://www.dovepress.com/selective-glycopolymer-inhibitors-of-galectin-3-supportive-anti-cancer-peer-reviewed-fulltext-article-IJN" target="_blank" >https://www.dovepress.com/selective-glycopolymer-inhibitors-of-galectin-3-supportive-anti-cancer-peer-reviewed-fulltext-article-IJN</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/IJN.S503381" target="_blank" >10.2147/IJN.S503381</a>
Alternative languages
Result language
angličtina
Original language name
Selective glycopolymer inhibitors of galectin-3: supportive anti-cancer agents protecting monocytes and preserving interferon-gamma function
Original language description
The immunosuppressive roles of galectin-3 (Gal-3) in carcinogenesis make this lectin an attractive target for pharmacological inhibition in immunotherapy. Although current clinical immunotherapies appear promising in the treatment of solid tumors, their efficacy is significantly weakened by the hostile immunosuppressive tumor microenvironment (TME). Gal-3, a prominent TME modulator, efficiently subverts the elimination of cancer, either directly by inducing apoptosis of immune cells or indirectly by binding essential effector molecules, such as interferon-gamma (IFNγ). N-(2-Hydroxypropyl)methacrylamide (HPMA)-based glycopolymers bearing poly-N-acetyllactosamine-derived tetrasaccharide ligands of Gal-3 were designed, synthesized, and characterized using high-performance liquid chromatography, dynamic light scattering, UV-Vis spectrophotometry, gel permeation chromatography, nuclear magnetic resonance, high-resolution mass spectrometry and CCK-8 assay for evaluation of glycopolymer non-toxicity. Pro-immunogenic effects of purified glycopolymers were tested by apoptotic assay using flow cytometry, competitive ELISA, and in vitro cell-free INFγ-based assay. All tested glycopolymers completely inhibited Gal-3-induced apoptosis of monocytes/macrophages, of which the M1 subtype is responsible for eliminating cancer cells during immunotherapy. Moreover, the glycopolymers suppressed Gal-3-induced capture of glycosylated IFNγ by competitive inhibition to Gal-3 carbohydrate recognition domain (CRD), which enables further inherent biological activities of this effector, such as differentiation of monocytes into M1 macrophages and repolarization of M2-macrophages to the M1 state. The prepared glycopolymers are promising inhibitors of Gal-3 and may serve as important supportive anti-cancer nanosystems enabling the infiltration of proinflammatory macrophages and the reprogramming of unwanted M2 macrophages into the M1 subtype.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10404 - Polymer science
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Nanomedicine
ISSN
1178-2013
e-ISSN
1178-2013
Volume of the periodical
20
Issue of the periodical within the volume
24 May
Country of publishing house
NZ - NEW ZEALAND
Number of pages
19
Pages from-to
6591-6609
UT code for WoS article
001496996200001
EID of the result in the Scopus database
2-s2.0-105007128024